Merck & Co., Inc. MRK
144.67 USD -3.69 (-2.49%)
At closeNov 4, 2026, 5:44 AM EST
146.40 +1.73 +1.20%
Pre-market · Nov 4, 5:44 AM ET
143.47 Day range 147.62
82.01 52-week range 156.92
- YTD
- +37.44%
- 1 year
- +75.38%
Analyst view
Consensus: buy
Buy
Price target (mean) 160.29 +10.8% upside
Now 144.67
- Target (low)
- 105.00
- Target (mean)
- 160.29
- Target (high)
- 186.00
Ratings (0m) 28 19 buy · 9 hold · 0 sell
- Strong buy5
- Buy14
- Hold9
- Sell0
- Strong sell0
Recommendation trend
- This month 28
- 1 month ago 28
- 2 months ago 27
- 3 months ago 28
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 1.77 | 1.70 – 1.96 | 2.04 | -13.4% | 16.31B | -0.5% | 19 |
| Next quarter | 2.13 | 1.97 – 2.27 | -1.28 | +266.3% | 16.44B | +0.9% | 9 |
| Current year | 2.77 | 2.50 – 2.99 | 8.98 | -69.2% | 67.20B | +3.4% | 26 |
| Next year | 9.02 | 8.45 – 9.75 | 2.77 | +226.0% | 69.50B | +3.4% | 24 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 2, 2026 | Freedom Broker | Maintained | Hold | Hold |
| Nov 2, 2026 | Cantor Fitzgerald | Maintained | Neutral | Neutral |
| Oct 30, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Oct 30, 2026 | RBC Capital | Maintained | Sector Perform | Sector Perform |
| Oct 30, 2026 | Guggenheim | Maintained | Buy | Buy |
| Oct 26, 2026 | Barclays | Maintained | Overweight | Overweight |
| Oct 12, 2026 | Citigroup | Maintained | Neutral | Neutral |
| Oct 12, 2026 | RBC Capital | Maintained | Sector Perform | Sector Perform |
| Oct 8, 2026 | Cantor Fitzgerald | Maintained | Neutral | Neutral |
| Oct 7, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Oct 5, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Sep 29, 2026 | Scotiabank | Maintained | Sector Outperform | Sector Outperform |
| Sep 10, 2026 | HSBC | Maintained | Buy | Buy |
| Sep 9, 2026 | Leerink Partners | Maintained | Outperform | Outperform |
| Sep 8, 2026 | Guggenheim | Maintained | Buy | Buy |
| Sep 4, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Aug 25, 2026 | Wolfe Research | Maintained | Outperform | Outperform |
| Aug 25, 2026 | Argus Research | Maintained | Buy | Buy |
| Aug 21, 2026 | Goldman Sachs | Maintained | Buy | Buy |
| Aug 20, 2026 | BMO Capital | Maintained | Outperform | Outperform |
| Aug 20, 2026 | UBS | Maintained | Buy | Buy |
| Aug 20, 2026 | RBC Capital | Downgrade | Outperform | Sector Perform |
| Aug 20, 2026 | Morgan Stanley | Upgrade | Equal-Weight | Overweight |
| Aug 12, 2026 | Daiwa Capital | Upgrade | Neutral | Outperform |
| Aug 11, 2026 | Argus Research | Maintained | Buy | Buy |
| Aug 5, 2026 | Guggenheim | Maintained | Buy | Buy |
| Jul 29, 2026 | Barclays | Maintained | Overweight | Overweight |
| Jul 13, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Jul 13, 2026 | BMO Capital | Maintained | Outperform | Outperform |
| Jul 13, 2026 | Guggenheim | Maintained | Buy | Buy |
